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Abstract. In our previous study, ribonucleotide reductase M2 
(RRM2) was identified as a cancer-related gene commonly 
overexpressed in human oral squamous cell carcinoma 
(OSCC) cell lines. Herein, we attempted to determine whether 
targeting RRM2 may be a plausible therapeutic approach for 
the treatment of patients with OSCC. First, we examined the 
expression levels of RRM2 in human OSCC cell lines and 
tissues. Overexpression of RRM2 in OSCC was confirmed by 
western blot analysis. Subsequently, we investigated the effects 
of a synthetic small interfering RNA specific for RRM2 
and gemcitabine (GEM), an inhibitor of RRM2 enzymatic 
activity, on the growth of human OSCC cell lines and primary 
cultured cells. Targeting RRM2 by RNA interference almost 
completely suppressed the expression of RRM2 and markedly 
suppressed the growth of both types of cells by >54.8%. GEM 
also reduced the growth rate of these cells by >83.0%. Finally, 
we evaluated the antitumor effects of GEM, cisplatin (CDDP), 
5-fluorouracil (5-FU), and docetaxel (DOC) against OSCC 
cells using the collagen gel droplet embedded culture drug 
sensitivity test. OSCC cells were more sensitive to GEM and 
DOC than to CDDP and 5-FU, regardless of the expression 
level of RRM2 mRNA. These results suggested that RRM2 
supported the growth of human OSCC cells and that targeting 
of RRM2, e.g., via GEM treatment, may be a promising thera-
peutic strategy for OSCC.
Introduction
More than 500,000 new cases of head and neck squamous cell 
carcinoma (HNSCC) occurred in 2008 worldwide. Oral squa-
mous cell carcinoma (OSCC) is the most frequently occurring 
cancer among HNSCCs and is associated with a mortality 
rate of approximately 50%, as reported in 2008 (1). Despite 
the increasing knowledge of OSCC pathogenesis, as well as 
advances in chemotherapy, radiotherapy, and surgery, little 
improvement in the relative survival rate has been observed in 
OSCC during the past several decades (2). Therefore, a greater 
understanding of the pathogenesis of OSCC is needed for the 
development of optimal therapeutic approaches.
Cancer cells acquire abnormalities in multiple oncogenes 
and tumor-suppressor genes. Overexpression and constitutive 
activation of some oncogenes support the proliferation, inva-
sion, and metastasis of cancer cells. Inactivation of a single 
critical oncogene can induce cancer cells to differentiate 
into cells with a normal phenotype or to undergo apoptosis. 
This dependence on oncogenes for maintaining the cancer 
phenotype is an Achilles heel for cancer cells, which can be 
exploited in cancer therapy (3).
In HNSCCs, including OSCC, the overexpression of 
epidermal growth factor receptor (EGFR) correlates with 
lymph node metastasis, risk of locoregional recurrence, and 
poor prognosis (4,5). Cetuximab, which targets EGFR, is 
used for patients with local advanced, recurrent, or metastatic 
HNSCC. Radiotherapy or platinum-based chemotherapy 
plus cetuximab improve locoregional control and overall 
survival (6,7). However, cetuximab is the only available 
molecular targeted drug for the treatment of OSCC. Thus, 
we previously attempted to identify useful target molecules 
for the treatment of OSCC using microarray analysis, and we 
identified 465 cancer-related genes that were commonly over-
expressed in human OSCC cell lines (8). Among these genes, 
overexpression of ribonucleotide reductase M2 (RRM2), 
which is targeted by gemcitabine (GEM), has been shown to 
be involved in tumor progression in human malignancies (9).
Ribonucleotide reductase (RR) catalyzes the conversion of 
ribonucleotide 5'-diphosphates to their 2'-deoxynucleotide form 
required for DNA synthesis. RRM2 is the catalytic subunit of 
RR and modulates its enzymatic activity (10-12). GEM binds 
to RRM2, replaces cytidine during DNA replication, and 
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inhibits RR, hence reducing deoxynucleotide pools; moreover, 
GEM also competes with deoxycytidine triphosphate for 
incorporation into elongating DNA strands and halts DNA 
polymerization (13). GEM has been used for the treatment 
of pancreatic cancer, biliary tract cancer, lung cancer, breast 
cancer, bladder cancer, and ovarian cancer. Furthermore, 
GEM has been applied in preclinical and clinical studies for 
head and neck cancer including OSCC (14-19).
Therefore, in this study, we examined the role of RRM2 
in OSCC using GEM, which targets RRM2, and RNA inter-
ference (RNAi). Our data show that RRM2 is an important 
molecular target that is involved in the pathogenesis of OSCC 
and that it could be a promising target for the treatment of 
OsCC.
Materials and methods
Cells and cell culture. We used four human OSCC cell lines: 
green fluorescent protein (GFP)-SAS (20), Ca9-22, HSC2, 
and HSC3, as previously described (21). All cell lines were 
maintained in Dulbecco's modified Eagle's medium (DMEM; 
Wako, Osaka, Japan) supplemented with 10% fetal bovine 
serum (FBS; Biosource, Camarillo, CA, USA), 100 U/ml peni-
cillin, and 100 µg/ml streptomycin (Wako), referred to here 
as complete medium. Primary cultured cells were established 
from OSCC tumors harvested from patients. Tumor tissues, 
including adjacent normal tissues, were surgically excised and 
rinsed several times with complete medium. The tumor and 
adjacent normal tissues were individually cut into small frag-
ments and dissociated at 37˚C for 2 h with 0.1% collagenase 
(Wako). The cell suspension was filtered through a cell strainer 
with 70-µm nylon mesh (BD, Franklin Lakes, NJ, USA). The 
cells were collected by centrifugation, resuspended in kera-
tinocyte serum-free medium (K-SFM; Life Technologies, 
Carlsbad, CA, UsA), seeded onto plastic tissue culture dishes, 
and grown in an incubator with a humidified atmosphere of 
95% air and 5% CO2 at 37˚C.
Small molecule compound. Gemcitabine hydrochloride 
(GEM; Wako) was dissolved in nuclease-free water to a stock 
concentration of 10 mM and stored at 4˚C until use.
Samples from patients. Twenty-five OSCC tissues from 
patients were obtained at the Ehime University Hospital from 
September 2008 to May 2014. The tissues were collected from 
resected specimens of primary tumors (17 men and 8 women; 
average age, 68.04 years). Three primary cultured cells were 
derived from OSCC of the lower gingiva (from a 55-year-old 
man, T4N2bM0), tongue (from a 57-year-old man, rT1N0M0), 
and skin metastasis (from a 61-year-old man, rT0N0M1). The 
Institutional Review Board (IRB) at Ehime University Hospital 
approved this study. All patients were enrolled after providing 
written informed consent.
Western blot analysis. Cells (5x105 for GFP-SAS, Ca9-22, 
HSC2, and HSC3) were grown in monolayers and lysed with 
lysis buffer [0.5 M EDTA (Dojindo, Kumamoto, Japan) and 1% 
NP-40 (Nacalai Tesque, Kyoto, Japan) in phosphate-buffered 
saline (PBS; Wako) containing a protease inhibitor and phos-
phatase inhibitor (Roche Diagnostics, Basel, Switzerland)]. 
Tissues were homogenized in 500 µl of lysis buffer with the 
use of a TissueLyser system (Qiagen, Valencia, CA, USA). The 
samples were centrifuged at 15,000 x g for 15 min at 4˚C, and 
supernatants were electrophoresed on SDS-polyacrylamide 
gels, followed by transfer to polyvinylidene difluoride 
membranes (Millipore, Bedford, MA, USA). The membranes 
were blocked with 5% nonfat dried milk (Wako) in 1X 
TBS-T [25 mM Tris-HCl, 125 mM NaCl, and 0.1% Tween-20 
(Sigma-Aldrich, St. Louis, MO, USA)] for 15 min at 37˚C. 
Membranes were then probed with monoclonal mouse anti-
human RRM2 antibodies (Abnova, Taipei, Taiwan; diluted 
1:500) or monoclonal mouse anti-β-tubulin antibodies (BD; 
diluted 1:1000) in 5% nonfat dried milk in 1X TBS-T for 1 h 
at room temperature, followed by treatment with horseradish 
perioxidase-conjugated secondary antibodies against mouse 
IgG (GE Healthcare, Buckinghamshire, UK) for 1 h at room 
temperature. The immune complexes were visualized using 
enhanced chemiluminescence (ECL) Prime western blotting 
detection reagent (GE Healthcare). The density of visualized 
immune complexes was quantified using an LAS-3000 system 
(Fujifilm, Tokyo, Japan).
Transfection with synthetic small interfering RNA (siRNA). 
We used Silencer Select siRNA targeting RRM2 (siRRM2) 
and Silencer Select Negative Control (siNT) purchased 
from Life Technologies. Transfections were performed with 
Lipofectamine RNAiMAX (Life Technologies) mixed with 
5 nM siRNAs for western blotting and cell growth assays.
Cell growth assay. Cells (2x103 GFP-SAS cells, 3x103 Ca9-22, 
HSC2, and HSC3 cells) were seeded into 96-well plates in 
complete medium with 5 nM synthetic siRNAs and 0.2% 
Lipofectamine RNAiMAX in a final volume of 100 µl. GEM 
was added to each well at different concentrations ranging 
from 1 to 1000 nM. After 72 h, cell growth was evaluated by 
WST-8 assay (Cell Counting Kit-8; Dojindo).
In vitro collagen gel droplet embedded culture drug sensi-
tivity test (CD-DST). The chemosensitivity of OSCC was 
evaluated using CD-DST kit (Primastar®; Kurabo, Osaka, 
Japan) according to manufacturer's protocol as described 
previously (22). The anticancer drugs tested in the CD-DST 
were GEM (Eli Lilly Japan, Kobe, Japan; 8.0 µg/ml for 
1 h), cisplatin (CDDP; Bristol-Myers Squibb, Tokyo, Japan; 
0.2 µg/ml for 24 h), 5-fluorouracil (5-FU; Kyowa Hakko Kirin, 
Tokyo, Japan; 1.0 µg/ml for 24 h) and 0.1 µg/ml docetaxel 
(DOC; Sanofi, Tokyo, Japan; 0.1 µg/ml for 24 h). In vitro 
sensitivity was expressed as the T/C (%), where T was the total 
volume of the treated group and C was the total volume of the 
control group. A T/C of 50% or less to each anticancer drug 
was regarded as in vitro sensitive (23).
Real-time quantitative reverse transcriptional polymerase 
chain reaction (qRT-PCR). Total RNA was extracted by 
lysing OSCC tissues with ISOGEN reagent (NipponGene, 
Toyama, Japan) after homogenization with a TissueLyser 
(Qiagen). The relative quantity of mRNA was determined 
using SYBR Green and the comparative CT method (∆CT 
method). Hydroxymethylbilane synthase (HMBS) was used 
as an internal control. PCR amplification was performed 
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in a 10 µl final reaction mixture containing 5 µl of 2X One 
Step SYBR RT-PCR Buffer 4, 0.4 µl of PrimeScript One 
Step Enzyme Mix 2 (Takara, Otsu, Japan), 0.4 µl of PCR 
forward and reverse primers (10 µM), 0.2 µl of ROX refer-
ence Dye II (x50), 2.6 µl of RNase-free dH2O, and 1 µl of 
total RNA (100 ng/µl). The thermal-cycling conditions were 
as follows: reverse transcription at 42˚C for 5 min and 95˚C 
10 sec, followed by 40 cycles at 95˚C for 5 sec and 60˚C 30 sec. 
SYBR Green I fluorescence was detected with ViiA™7 (Life 
Technologies). The sequences of primers used were as follows: 
RRM2: forward 5'-TGC GTC GAT ATT CTG GCT CAA G-3' 
and reverse 5'-CCG ATG GTT TGT GTA CCA GGT G-3'; 
HMBS: forward 5'-CAT GCA GGC TAC CAT CCA TGT C-3' 
and reverse 5'-GTT ACG AGC AGT GAT GCC TAC CAA-3'.
Statistical analysis. All in vitro experiments were performed 
in triplicate and repeated three times. All statistical analyses 
were performed using GraphPad Prism software, version 5.04 
(GraphPad Software, San Diego, CA, USA). Student's t-tests 
were used to determine the significance of differences between 
the groups. Log-rank tests were used to analyze survival rates. 
Differences with P-values of <0.05 were considered statisti-
cally significant.
Results
Overexpression of RRM2 protein in OSCC. First, we examined 
the expression of RRM2 protein in four human OSCC cell lines 
and human normal oral mucosa epithelial primary cultured cells 
Figure 1. Expression of RRM2 protein in OSCC. (A) RRM2 protein expression in human OSCC cells was detected by western blotting. RRM2 protein is shown 
as two bands, with the upper band indicating phosphorylated RRM2. (B) RRM2 protein expression in the tumors and adjacent normal tissues from the same 
patient, as analyzed by western blotting. N, normal tissues; T, tumor tissues.
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by western blotting. The expression levels of RRM2 protein 
in all OSCC cells were >2-fold higher than those in human 
normal oral mucosa epithelial cells (Fig. 1A). Subsequently, 
we compared the expression levels of RRM2 protein in OSCC 
tumors and adjacent normal mucosa tissues from the same 
patient; in these samples, we found 1.5- to 5.7-fold higher 
expression in RRM2 protein in tumor tissues than in normal 
tissues (Fig. 1B). Thus, these data supported that RRM2 protein 
was overexpressed in OsCC tissues and cultured cells.
Growth inhibitory effects of siRRM2 in human OSCC cells 
in vitro. To clarify the function of RRM2 in the proliferation of 
human OSCC cells, we transfected GFP-SAS, Ca9-22, HSC2, 
and HSC3 cells with 5 nM siRRM2. Targeting RRM2 by RNAi 
suppressed the expression of RRM2 protein by >58% compared 
to siNT and significantly inhibited the growth of human OSCC 
cell lines by >81.5% (Fig. 2A and B). Furthermore, in primary 
cultured cells obtained from culture of resected tumor tissues 
from OSCC patients, knockdown of RRM2 expression also 
Figure 2. Growth inhibitory effects of siRRM2 in human OSCC cells in vitro. (A and C) Synthetic siRRM2 (5 nM) was transfected into human OSCC cell 
lines (GFP-SAS, Ca9-22, HSC2, and HSC3) and three primary cultured cells using Lipofectamine RNAiMAX for 24 h. (B and D) Human OSCC cells were 
seeded in complete medium with synthetic siRNAs for 72 h, and cell growth was analyzed. Bars denote the standard deviations (SDs) of samples analyzed in 
triplicate. *P<0.01 compared to control culture. siNT, non-targeting siRNA.
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suppressed the growth of OSCC primary cultured cells by 
>54.8% (Fig. 2C and D).
Antitumor effects of GEM in human OSCC cells in vitro. Next, 
we examined the effects of GEM on the inhibition of RRM2 
activity on the growth of human OSCC cell lines and primary 
cultured cells. In both types of cells, GEM markedly reduced 
the cell growth rate in a concentration-dependent manner. The 
growth rate of all OSCC cells was decrease >83.0% following 
treatment with 1000 nM GEM (Fig. 3A and B).
In vitro chemosensitivity of OSCC. Next, we evaluated the 
chemosensitivity of 25 OSCC tumors to GEM, CDDP, 5-FU, 
and DOC using CD-DST. From this analysis, we found that 
16 cases (64%) were sensitive to GEM, with an average T/C 
value of 42.6%. OSCC tumors were more sensitive to GEM 
and DOC than to CDDP and 5-FU (Table I).
Clinical significance of GEM sensitivity and RRM2 mRNA 
expression in OSCC. Finally, we examined RRM2 mRNA 
expression levels by qRT-PCR in OSCC cases and investigated 
the relationship between GEM sensitivity, RRM2 mRNA 
expression levels, and prognosis (overall, disease-specific and 
disease-free survival) in OSCC cases. However, there were 
no significant correlations or differences among these factors 
(data not shown).
Discussion
In this study, we examined the expression and function of 
RRM2 in OSCC. Our data demonstrated that RRM2 was over-
expressed in OSCC cells and primary culture cells derived 
from patient tumors and that inhibition of RRM2 via GEM or 
siRRM2 suppressed cell growth of OSCC cells. Thus, RRM2 
may represent a novel target for anticancer therapy in OSCC.
RRM2 overexpression has been shown to be significantly 
associated with tumor progression or survival in many types 
of cancer (9,24-26). Ectopic expression of RRM2 induces 
membrane-associated Raf1 expression and MAPK2 and 
Rac-1 activation, resulting in enhanced metastatic potential in 
a xenograft model (27). In addition, a previous study showed 
that HNSCC cells overexpress RRM2 and that knockdown 
of RRM2 by RNAi significantly reduces the growth of 
hNsCC cells in vitro and in vivo (28). Herein, we showed 
that RRM2 was overexpressed in OSCC and demonstrated 
the growth inhibitory effects of targeting RRM2 by RNAi in 
human OSCC cells. A recent study showed that knockdown of 
RRM2 expression promotes apoptosis by suppressing Bcl-2 
protein expression in HNSCC and non-small cell lung cancer 
(NsCLC) cells. RRM2 suppression contributes to the insta-
bility of Bcl-2 or causes Bcl-2 to remain unprotected from 
degradation. Thus, RRM2 may be an attractive interventional 
target to downregulate Bcl-2, resulting in the induction of 
mitochondria-mediated intrinsic apoptosis (26). Therefore, 
targeting RRM2 may be an appropriate therapeutic approach 
for the treatment of these cancers.
GEM, triapine, and GTI-2040 are known RRM2 inhibi-
tors (29-31). Triapine and GTI-2040 have been evaluated in 
phase I clinical trials (30,31). GEM competes with RRM2 
for replicating DNA and is a potential candidate for RRM2 
inhibition that has been approved by the US Food and Drug 
Administration for the treatment of NSCLC, pancreatic cancer, 
ovarian cancer, and breast cancer. however, GEM has not been 
approved for the treatment of OSCC.
Currently, CDDP-based chemotherapy is generally the 
first-line treatment for inoperable recurrent or metastatic 
OSCC because we cannot predict the efficacy of chemo-
therapy. CD-DST can mimic in vivo tumor growth using 
Figure 3. Antiproliferative effects of GEM in human OSCC cells in vitro. 
Human OSCC cell lines, i.e., GFP-SAS, Ca9-22, HSC2 and HSC3 (A), and 
three primary cultured cells (B) were seeded in complete medium. Twenty-
four hours later, GEM was added to each well at final concentrations of 0, 1, 
10, 100, or 1000 nM. After 72 h, cell viability was evaluated by WST-8 assay. 
Bars denote the SDs of samples analyzed in triplicate. *P<0.01 compared to 
the control culture.
Table I. CD-DST in OSCC cases (n=25).
Anticancer drugs GEM CDDP 5-FU DOC
Average T/C (%) 42.6±30.5 73.5±21.7 82.4±17.5 41.1±24.5
Sensitive case (n) 16 1 5 18
P-value  <0.001 <0.001 0.697
A T/C of 50% or less to each anticancer drug was regarded as sensi-
tive. CD-DST, collagen gel droplet embedded culture drug sensitivity 
test; GEM, gemcitabine; CDDP, cisplatin; 5-FU, 5-fluorouracil; DOC, 
docetaxel; T/C, total colony volume of the treated cells/total colony 
volume of the untreated cells.
IwAMOTO et al:  RRM2 IS A PROMISING THERAPEUTIC TARGET IN OSCC1976
type I collagen to create a three-dimensional culture system 
and individually evaluate the response to chemotherapeutic 
drugs. Several clinical studies have reported that CD-DST 
may be useful when devising optimal treatment strategies 
for NSCLC (23), ovarian (32), gastrointestinal (33), or colon 
cancer (34). In patients with HNSCC, CD-DST can be also 
used to predict CDDP sensitivity and guide individualized 
chemotherapy (35). Thus, CD-DST has been approved for 
use in the evaluation of cancer treatments by the Ministry of 
Health, Labour and Welfare of Japan. In the present study, 
CD-DST indicated that GEM and DOC had more potent anti-
tumor activity against OSCC than CDDP and 5-FU. CDDP 
plus 5-FU (PF) chemotherapy is the most widely used therapy 
in the treatment of patients with OSCC. The resistance of 
tumor cells to PF remains a major cause of treatment failure. 
Therefore, GEM may be a useful second-line chemotherapy 
for PF-resistant OSCC.
The relationship between RRM2 mRNA expression levels 
and the response to GEM in the clinical setting has been inves-
tigated in various cancers. In pancreatic cancer, the response 
rate to GEM is significantly higher in patients with low RRM2 
mRNA expression in biopsy specimens (36). Furthermore, in 
patients with lung adenocarcinoma, low levels of RRM2 mRNA 
are associated with the response to GEM plus DOC (24). These 
results indicate the possibility that expression levels of RRM2 
mRNA could predict chemosensitivity to GEM. However, 
there was no significant correlation between GEM sensitivity 
and RRM2 mRNA expression levels in patients with OSCC in 
this study. Thus, there is still no molecular marker available to 
predict the response to GEM in OsCC.
In conclusion, our data suggest that RRM2 plays a critical 
role in supporting the growth of human OSCC cells, and 
agents targeting RRM2, such as GEM, appear to be a poten-
tially useful therapeutic approach for OSCC.
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